NEXGEL Issues Preliminary Revenue Results and Business Update

On January 22, 2025, NexGel, Inc. released a press release detailing various business updates and offering preliminary, unaudited summary revenue results for the fourth quarter and year ending December 31, 2024. The results provided in the press release are subject to customary quarter-end adjustments. The company highlighted a revenue expectation of approximately $3.0 million for the fourth quarter of 2024 and projected total revenue for the year to be around $8.6 million, showcasing growth exceeding 100% year-over-year for the third consecutive year.

NexGel anticipates revenue generation of at least $13 million for 2025, with a focus on achieving positive cash flow from operations throughout the year. The company specializes in providing medical and over-the-counter products, notably ultra-gentle, high-water-content hydrogels for healthcare and consumer applications.

The core segments driving NexGel’s growth strategy include contract manufacturing and white label services, consumer products, and aspirational medical device development. The company reported significant expansion in consumer products in 2024, citing successes from brands like Medagel, Kenkoderm, and Silly George, alongside a strategic partnership with Stada.

Moving forward, NexGel has outlined plans for the upcoming year, aiming to capitalize on growth opportunities across its key business segments. The company remains committed to delivering long-term value for its shareholders and expressed optimism for the future amidst various market dynamics and innovative initiatives.

This information, provided in a Form 8-K filing with the Securities and Exchange Commission, showcases NexGel’s strategic direction and financial performance trends. The company continues to aim for sustained growth and operational efficiency in the competitive marketplace. Investors and stakeholders are encouraged to stay informed about NexGel’s progress and future developments.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NEXGEL’s 8K filing here.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.